{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-158751","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2024-06-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.254547+00:00","generated_at":"2026-06-01T05:09:09.221120+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NewAmsterdam Pharma obtains composition of matter patent for obicetrapib extending IP to July 2043","bullets":["USPTO issued patent 12,006,305 covering amorphous obicetrapib hemicalcium, the product form for potential commercialization.","Patent protection extends to July 2043, over 9 years beyond prior second-generation patent expiration in 2034.","Nine total patents now issued or allowed by USPTO covering obicetrapib and its uses.","Patent eligible for listing in FDA Orange Book as drug substance patent if product approved."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-158751","json":"https://secwatch.observer/filing/0001193125-24-158751.json","markdown":"https://secwatch.observer/filing/0001193125-24-158751.md","text":"https://secwatch.observer/filing/0001193125-24-158751.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000119312524158751/0001193125-24-158751-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000119312524158751/d851893d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:09:09.221120+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}